The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
Proprietary consumer insights on attitudes, uses and behaviours
Deep dives into the most transformative compounds and companies
Key regulations, transformative trends and commercial opportunities
PSYCH: What are the next steps
PSYCH: What Lies Ahead?
The Future of Therapy
PSYCH: Psychedelics for
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS AND INSIGHTS
Results of Major Study on Impact of Microdosing Published
Researchers from Imperial College London have carried out the largest placebo-controlled trial into psychedelics to date and found that small doses of LSD boost the psychology of users in a manner of ways. However, when the researchers examined what trial volunteers took, they found placebos worked equally as well as the drug. In short, theContinue reading
During The PSYCH Symposium in November 2020, a panel of leading scientists discussed their work in the field of psychedelic medicines as well as the research they had conducted on microdosing and the impact it has on the human body. Does it increase creativity? Improve focus or nothing more than a silicon valley fad? FindContinue reading
During The PSYCH Symposium in November 2020, a panel of leading experts operating in psychedelics sector, discussed the cultural challenge of commercialising the likes of psilocybin, DMT and LSD. This discussion, featuring a number of leading voices from across the psychedelics spectrum, focused on the problems which may arise as a result of removing theContinue reading
"Given the escalating magnitude of the mental health crisis, the need to address this epidemic has never been as accentuated. We strongly believe that the growth potential within this industry is of staggering proportions."
The German startup @ATAI_life, which is exploring the use of psychedelic substances to treat mental health disorders, has been valued at about US$2 billion in a funding round ahead of its potential listing.
The PSYCH Virtual Investor Summit: Europe & Asia, will connect a qualified investor community in Europe and Asia with the leaders from the most innovative and exciting businesses operating in the global psychedelic industry.
Secure your place, here: